|Trade names||Debridat, Recutin, Polybutin, others|
|AHFS/Drugs.com||International Drug Names|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||387.476 g·mol−1|
|3D model (JSmol)|
|(what is this?)|
The major product from drug metabolism of trimebutine in human beings is nortrimebutine, which comes from removal of one of the methyl groups attached to the nitrogen atom. Trimebutine exerts its effects in part due to causing a premature activation of phase III of the migrating motor complex in the digestive tract.
Both trimebutine and its metabolite are commercially available.
- Kaneto H, Takahashi M, Watanabe J (July 1990). "The opioid receptor selectivity for trimebutine in isolated tissues experiments and receptor binding studies". Journal of Pharmacobio-Dynamics. 13 (7): 448–53. doi:10.1248/bpb1978.13.448. PMID 1963196.
- Roman FJ, Lanet S, Hamon J, Brunelle G, Maurin A, Champeroux P, et al. (June 1999). "Pharmacological properties of trimebutine and N-monodesmethyltrimebutine". The Journal of Pharmacology and Experimental Therapeutics. 289 (3): 1391–7. PMID 10336531.
- Hiyama T, Yoshihara M, Tanaka S, Haruma K, Chayama K (April 2009). "Effectiveness of prokinetic agents against diseases external to the gastrointestinal tract" (PDF). Journal of Gastroenterology and Hepatology. 24 (4): 537–46. doi:10.1111/j.1440-1746.2009.05780.x. PMID 19220673.
- Jhee OH, Lee YS, Shaw LM, Jeon YC, Lee MH, Lee SH, Kang JS (January 2007). "Pharmacokinetic and bioequivalence evaluation of two formulations of 100 mg trimebutine maleate (Recutin and Polybutin) in healthy male volunteers using the LC-MS/MS method". Clinica Chimica Acta; International Journal of Clinical Chemistry. 375 (1–2): 69–75. doi:10.1016/j.cca.2006.06.006. PMID 16854404.